It has recently been suggested that the anti‐proliferative effects of OTS167 on breast cancer cells are mediated through off‐target effects, as MELK‐knockout cell lines remained sensitive to the inhibitor (Huang et al, 2017; Lin et al, 2017); however, no such findings have been reported in other cancer types to date. This evidence concerns the gene MELK and breast carcinoma.